Windy City Media Group Frontpage News

THE VOICE OF CHICAGO'S GAY, LESBIAN, BI, TRANS AND QUEER COMMUNITY SINCE 1985

home search facebook twitter join
Gay News Sponsor Windy City Times 2023-12-13
DOWNLOAD ISSUE
Donate

Sponsor
Sponsor
Sponsor

  WINDY CITY TIMES

Microbicide research makes history at AIDS '10
2010-07-28

This article shared 3785 times since Wed Jul 28, 2010
facebook twitter google +1 reddit email


Analysis by Jim Pickett

Research into new HIV prevention technologies scored a huge victory July 20 at the XVIII International AIDS Conference ( AIDS 2010 ) in Vienna, Austria. There was nary a dry eye in the house.

At 1 p.m. that day, the husband and wife team of Drs. Salim S. Abdool Karim and Quarraisha Abdool Karim, from the Centre for the AIDS Programme of Research in South Africa ( CAPRISA ) , announced that a vaginal gel had been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes too. ( Microbicides are substances currently in development that are designed to reduce or prevent the sexual transmission of HIV or other sexually transmitted infections when applied either in the vagina or the rectum. )

The microbicide gel the Karims studied contained 1 percent tenofovir—an antiretroviral drug commonly used to treat people living with HIV—and was found to be 39 percent effective in reducing a woman's risk of becoming infected with HIV during vaginal intercourse and a whopping 51 percent effective in preventing genital herpes infections among the women in the trial. The protective effects against HIV increased as the use of tenofovir increased, so that women who used the gel in more than 80 percent of their sex acts during the trial had a 54 percent reduction in HIV infections.

If and when other studies of tenofovir gel confirm these results, widespread use of the gel, at this level of protection, could prevent millions of new HIV infections among women over the next two decades. This is especially important for South Africa, where the global pandemic is the most severe. In rural Vulindlela, outside Durban, one of the trial's two sites, the prevalence of HIV among young women exceeds 50 percent by the time they reach the age of 24. A microbicide gel would put the power of prevention in these women's hands, especially important where monogamy is not a guarantee and condom negotiation is difficult.

At the conclusion of the Karim's presentation, an overflow of more than 5,000 researchers and advocates stood up and gave them a prolonged standing ovation. Hugs, tears, and high fives heightened the excitement and electricity in the air—none of which normally ( ever? ) punctuate a summary of scientific data.

It was impossible not to feel deeply moved—the audience was witnessing first-hand a historic turning point in the epidemic. We will always remember "before CAPRISA" and "after CAPRISA." The situation before was looking a little grim; many years of research had not yet delivered a product that showed any signs of efficacy. After CAPRISA, it's not exactly rainbows and lollipops, as there is much to be done to confirm and extend these findings and make this drug available… once everyone has dabbed their eyes. But it's quite lovely nonetheless.

As an important aside, tenofovir is also being studied as a form of oral pre-exposure prophylaxis, in which HIV-negative individuals take the drug to prevent HIV transmission. Initial data from a safety and behavioral study conducted by the U.S. Centers for Disease Control and Prevention among 400 men in the United States were reported at AIDS 2010 as well.

"We didn't find any increased risk of harm in medical terms, and on the behavioral side the preliminary work we've done also suggests there is no increased risk," the CDC's Lisa Grohskopf, who led the study and presented the findings, told Reuters.

Later this year or in early 2011, data from the iPrEx Phase III trial will be released. The study will report on approximately 3,000 gay men and other men who have sex with men ( MSM ) from the United States, Peru, Ecuador, Brazil, Thailand and South Africa who are taking the antiretroviral Truvada ( a combination of tenofovir and emtricitabine ) , or a placebo, every day to see if the drug works to prevent HIV infection.

Back to CAPRISA: What do these new findings mean for rectal microbicides? After all, products that can be applied rectally to prevent HIV are important to the millions of gay men and women who practice receptive anal intercourse and need options beyond condoms as well.

"The positive results from the CAPRISA study represent a very significant milestone in HIV prevention research and they increase optimism that we can develop safe and effective antiretroviral rectal microbicides," said University of Pittsburgh's Dr. Ian McGowan, International Rectal Microbicide Advocates ( IRMA ) Scientific vice-chair and co-principal investigator of the Microbicide Trials Network. "Phase I rectal safety studies with tenofovir are ongoing and these efforts need to be intensified to help us move forward to rectal microbicide effectiveness studies as quickly as possible," he said.

Anal intercourse is a common human sexual behavior, practiced by approximately 5-10 percent of the world's general population, including heterosexual women and men, gay men, and other MSM. Because an act of unprotected anal intercourse is 10 to 20 times more likely to result in HIV transmission compared to unprotected vaginal intercourse, it is likely that unprotected anal intercourse is a significant driver in the HIV epidemic overall.

We know that unprotected anal intercourse is the chief cause of HIV infection for gay men/MSM across the world. But the world has largely ignored gay men, and anal intercourse. Gay men are underrepresented in most national AIDS strategies, in epidemiology, surveillance, and in research—if they show up at all. They have been woefully underserved by prevention, care, treatment and support services. Similarly, there is a paucity of data regarding anal intercourse—homosexual and heterosexual—due to politics, stigma, criminalization, and outright denial.

Globally, gay men/MSM are 19 times more likely to be HIV infected compared to the general population. These disproportionate rates extend to Africa, where the epidemic is often characterized as "heterosexual." For instance, according to data from Dr. Chris Beyrer presented at the Global Forum on MSM and HIV's "Be Heard!" pre-conference July 17, HIV prevalence among gay men/MSM in Malawi is 21.4 percent compared to 11.5 percent in the general population; in Kenya, 15.2 percent of gay/MSM are HIV+ compared to 6.1 percent of the general population. Previously reported data from Beyrer revealed that in Uganda, HIV prevalence rates among gay men and other MSM are just above 40 percent compared to 5 percent for other Ugandan men of reproductive age. And in South Africa, the prevalence rates between gay men/MSM and men of reproductive age are almost the same—both hovering around 15 percent.

Data released by the U.S. Centers for Disease Control and Prevention in early 2010 revealed that gay men/MSM in the United States are 44 times more likely to be HIV-positive than other men, and 40 times more likely to be HIV-positive than women.

The bottom line is that for the men and women who engage in anal intercourse, condoms work quite well to prevent HIV, but many people do not use them, or are simply unable to use them due to a number of issues including power dynamics in sexual relationships, stigma, and a serious lack of availability. According to the Global HIV Prevention Working Group, only 9 percent of individuals at risk for HIV infection had access to condoms in 2008. Condom-compatible lubricants are also in dangerously short supply, especially in Africa. Options are needed.

While the rectal microbicide field has gained significant momentum, more focus and resources are necessary. In 2010, U.S. $7.2 million are being spent globally on rectal microbicide research. IRMA has calculated that annual investments must increase by 40 percent from 2011-2014, to U.S. $10 million/year and must increase further to U.S. $44 million ( a six-fold increase ) in the years 2015-2020 to ensure a minimum of candidate products are moving through the research pipeline into late stage testing for effectiveness.

Advocates are optimistic that the CAPRISA results will not only accelerate the development of safe and effective vaginal microbicides, but that this proof of concept will also be translated into more financial and creative energy into rectal microbicide development. With five new infections for every two individuals beginning treatment, it's absolutely imperative we find new ways to prevent HIV for individuals at risk, gay and straight, women and men.

CAPRISA enrolled 889 women into a double-blind, placebo-controlled, randomized clinical trial. They were instructed to use the gel up to 12 hours before sex and soon after having sex for a maximum of two doses in 24 hours. Participants used the gel for a minimum of one year and a maximum of two and a half years. HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits for 30 months. They were asked to return all used and unused gel applicators. A total of 181,000 applicators were dispensed during the study.

In a word, these women were asked to do a lot. And 843 of them did all of that to the very end, with the study achieving a truly extraordinary 95-percent retention rate. The standing ovation, the hugs, and the tears were as much for the scientists as for these incredibly dedicated women and their exceptional, unwavering commitment to making a difference in the epidemic.

IRMA is a global network of advocates, scientists, policy makers and funders from six continents working together to advance a robust rectal microbicide research and development agenda. IRMA is based in the United States at the AIDS Foundation of Chicago with chapters in Latin America and Nigeria. For further information on IRMA visit www.rectalmicrobicides.org and read IRMA's new report, From Promise to Product: Advancing Rectal Microbicide Research and Advocacy. The report provides an overview of the maturing rectal microbicide field, updates the resource tracking exercise IRMA last conducted in 2006, and lays out global advocacy goals and objectives. Importantly, it also calls for the creation of a Global Rectal Microbicide Development plan, which would provide the foundation necessary to move the field from pre-clinical studies through Phase III efficacy trials—from promise to product.


This article shared 3785 times since Wed Jul 28, 2010
facebook twitter google +1 reddit email

Out and Aging
Presented By

  ARTICLES YOU MIGHT LIKE

Gay News

HIV criminal laws disproportionately impact Black men in Mississippi 2024-02-21
--From a press release - A new report by the Williams Institute at UCLA School of Law finds that at least 43 people in Mississippi were arrested for HIV-related crimes between 2004 and 2021. Half of all arrests in the state ...


Gay News

'West Side Story' gets a sex-positive spin with new burlesque show 2024-02-19
- In partial observance of National Condom Day, which was Feb. 14, Los Angeles-based AIDS Healthcare Foundation (AHF) presented A West Side Story Burlesque at the Harris Theater for two hour-long performances on Feb. 17. The show, ...


Gay News

$200,000+ raised at AIDS Foundation Chicago's World of Chocolate Fundraiser to fight HIV/AIDS 2024-02-13
--From a press release - (Chicago, IL) More than 950 guests gathered at Chicago's famed Union Station (500 W. Jackson) for Chicago's Sweetest Fundraiser, AIDS Foundation Chicago's (AFC), World of Chocolate on Friday, February 9. ...


Gay News

Munar prepares to step away from Howard Brown leadership 2024-02-11
- After 10 years of leadership at Howard Brown Health, President and CEO David Ernesto Munar has decided to step down from his post on Feb. 29. Munar, who'd previously been president and CEO of AIDS Foundation ...


Gay News

National Black Justice Coalition commemorates National Black HIV/AIDS Awareness Day 2024-02-07
--From a press release - WASHINGTON — Today, Feb. 7, marks National Black HIV/AIDS Awareness Day (NBHAAD). In commemoration, Dr. David J. Johns, CEO of the National Black Justice Coalition (NBJC), a leading Black LGBTQ+/same-gender ...


Gay News

NATIONAL Wis. report, gender dysphoria, HIV research, Stonewall exhibit, gay CEOs 2024-01-19
- A new annual report from Wisconsin's Office of Children's Mental Health shows that the state's minors—especially girls, children of color and LGBTQ+ youth—continue to struggle with anxiety, depression and thoughts ...


Gay News

WORLD Activist honored, marriages in Estonia, Madrid law, trans sports item 2024-01-05
Video below - The National AIDS Commission (NAC) recently honored Caleb Orozco—a leading figure in the fight for LGBTQ+ rights in Belize—for his instrumental contributions to the national HIV response, BNN reported. According ...


Gay News

SAVOR World of Chocolate, Jaleo and 'Superhot' 2023-12-31
- World of wonder: I am excited to announce that I will be a judge at AIDS Foundation Chicago's World of Chocolate fundraiser! Join me in sampling delicious chocolate from local chefs and help support a great ...


Gay News

PASSAGES Frankie Franklin-Foxx 2023-12-18
- Frankie Franklin-Foxx (born Waverlynn Franklin), a resident of Chicago's North Side, passed away peacefully Dec. 13 at St. Francis Hospital in Evanston. She was 68. Born at Cook County Hospital, Frankie graduated from South Shore High ...


Gay News

NATIONAL Dr. Rachel Levine, World AIDS Day, trans deaths, Philly bar art 2023-12-08
- United States District Court for the Northern District of Alabama Liles C. Burke ruled that emails and other records from U.S. Assistant Secretary for Health Dr. Rachel Levine are relevant to a lawsuit challenging Alabama's ban ...


Gay News

STRUT marks World AIDS Day with 14th Annual Fashion Show 2023-12-05
- On Dec. 3, John Fleming and Madman Productions presented the 14th annual STRUT fashion show at Joe's on Weed Street, 940 W. Weed St. As in previous years, the standing room only show was a fundraiser, ...


Gay News

World AIDS Day commemorated at AIDS Garden Chicago 2023-12-03
- On the rainy morning of Dec. 1, Chicago Parks Foundation and the AIDS Garden Chicago Board of Directors hosted a World AIDS Day commemoration at AIDS Garden Chicago, just south of Belmont Harbor on the Lakefront. ...


Gay News

GLAAD marks World AIDS Day with launch of global resource hub, new HIV report 2023-12-01
--From a press release - New York, New York — Friday, Dec. 1 — GLAAD marked World AIDS Day this year by sharing the results of its fourth annual State of HIV Stigma Report, a national survey among U.S. adults measuring ...


Gay News

Wrightwood 659 to present 'Daniel Goldstein: The Marks We Leave Behind' on World AIDS Day 2023-11-29
- (CHICAGO, Nov. 29, 2023) —Alphawood Exhibitions will present Daniel Goldstein: The Marks We Leave Behind, an exhibition of works from the San Francisco-based artist & HIV/AIDS activist's iconic "Icarian Series," ...


Gay News

WTTW doc chronicles the activism of Danny Sotomayor 2023-11-03
- Practically everything the late Chicago AIDS activist Danny Sotomayor did was "a fight." So says fellow activist Victor Salvo in the new WTTW documentary The Outrage of Danny Sotomayor, which is part of the station's Chicago ...


 


Copyright © 2024 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.

All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transgender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 
 

TRENDINGBREAKINGPHOTOS






Donate


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam     
Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.